Tumori non epiteliali dell’utero
Angiolo Gadducci
(Pisa)
Torino, 26 febbraio 2010
I tumori del corpo dell’utero: strategie terapeutiche in evoluzione
Uterine Sarcoma: Survival by stage
Stage patients 5-year Survival Histology
I 113 53%
LMS II-IV 50 8%
I 23 55%
ESS
II-IV 42 12%
I 82 50%
CS II-IV 100 12%
From Salazar and Dunne, 1980
Prognostic relevance of histology in uterine sarcoma
Salazar
1980Not
Wheelock
1985Not
George
1986Not
Kahanpaa
1986Not
Covens
1987Not
Echt
1990Not
Malmstrom
1992Not
Olah
1992Yes
Wolfson
1994Not
CTF
2000Yes
Authors Prognostic relevance
Variables predictive of survival by Cox proportional hazard model (423 pts)
RR (95% CI) p value
Stage (I, II, III, IV) 4.89 (4.08-5.87) <0.0001
Grade (G1,G2, G3) 3.02 (2.48-3.67) <0.0001
Age (continous) 1.81 (1.59-2.06) <0.0001
Histology (CS, LMS) 1.45 (1.25-1.68) 0.03
From Olah, 1992
Variables predictive of survival by Cox proportional hazard model (249 pts)
Variable Wald χχχχ2 Risk Ratio 95% Confidence p value Limits
Stage
I reference
II 1.58242 1.680 0.749-3.768 0.2084
III 16.04944 2.586 1.625-4.117 0.0001
IV 38.90724 4.613 2.853-7.457 0.0001 Mitotic count (mitoses per 10 HPF)
<10 reference
10-20 3.07388 1.887 0.928-3.837 0.0796
>20 12.69189 3.346 1.722-6.502 0.0004
Histologic type
LMS reference
LG-ESS 4.27787 0.257 0.071-0.931 0.0386
HG-ESS 0.04206 0.951 0.586-1.543 0.8375 CS 8.59031 0.509 0.324-0.799 0.0034
Gadducci for CTF 2000
Characteristics of CS
Dominant role of the epithelial component
Relatively high incidence of lymph node involvement
Sensitivity to CDDP-based CT
Better clinical outcome compared with LMS
Hysterectomy and bilateral salpingo-oophorectomy is the gold standard for tumors limited to the uterine corpus
Ovaries could be preserved in young patients with LMS
Surgery in uterine sarcoma
Surgery pts recurrence rate
TAH + BSO 26 76.9%
TAH + MSO 8 62.5%
TAH + BSO 21 33%
TAH + MSO 21 24%
10-y DFS
TAH + BSO 25* 57%
TAH + MSO 25* 58%
*matched by stage, grade and age
Stage I-II LMS
recurrence by ovarian surgery
from Berchuck, 1990
from CTF, 1996
from Giuntoli, 2003
Comprehensive surgical staging (peritoneal cytology and biopsies, omentectomy, pelvic and para-aortic lymph node dissection) and, when
appropriate, tumor debulking is warranted in CS
In others histologic subtypes, lymphadenectomy should be performed only in pts with enlarged nodes discovered at the time of the surgical procedure
Surgery in uterine sarcoma
Adjuvant RT in uterine sarcomas
Authors Decrease in local failure Improvement in survival Salazar 1980 yes not
George 1986 yes not Kahanpaa 1986 yes not Nielsen 1989 yes not Echt 1990 yes not Ali 1993 yes not Tinkler 1993 not not Manchul* 1994 yes yes
CTF 1996 yes not
Chi 1997 yes not Gerszten* 1998 yes yes Ferrer 1999 yes yes Yamada* 2000 yes not Demiaud-Alexandre 2001 yes not Soumarova 2002 yes yes Weitmann** 2002 yes not
Giuntoli 2003 yes not
*CS;**ESS
Recurrent disease in pts with stage I-II uterine sarcomas
Histology Patients Recurrence Median time Sites of recurrence to recurrence P D P+D LMS 90 35 (39%) 18 mos 5 23 7
(14%) (66%) (20%)
LG-ESS 20 5 (25%) 36 mos 5 0 0 HG-ESS 20 11 (55%) 5 mos 3 4 4
(27%) (36%) (36%)
CS 66 27 (41%) 8 mos 10 11 6
(37%) (41%) (22%)
196 78 (40%) 23 38 17
(29%) (49%) (28%) Gadducci for CTF, 1997
Totally resected stage I/II high-grade uterine sarcoma
Adjuvant pelvic
RT Observation
RANDOM
versus
Phase III randomised study to evaluate the role of adjuvant pelvic RT in uterine sarcomas stages I and II: An EORTC-CGCG study
from Reed 2008
DFS by treatment OS by treatment
Log-rank: p=0.3524
Log-rank: p=0.9231
Phase III randomised study to evaluate the role of adjuvant pelvic RT in uterine sarcomas stages I and II: An EORTC-CGCG study
from Reed 2008
Any local recurrence 11 (24%) 21 (47%) 10 (20%) 12 (24%) Any distant metastases 16 (35%) 13 (29%) 27 (54%) 16 (33%)
RT (n = 46)
control (n = 45)
RT (n = 50)
control (n = 49)
CS (n. 91) LMS (n.99)
Phase III randomised study to evaluate the role of adjuvant pelvic RT in uterine sarcomas stages I and II: An EORTC-CGCG study
from Reed 2008
Sites of recurrence
DOX and IFO in uterine sarcomas:
Data from GOG trials
DOX 60 mg/m2 pts RR (%)
LMS* 28 25.0
CS* 41 9.8
IFO (+ MESNA) 1.5 g/m2 daily x 5
CS** 28 32.2
LMS** 35 17.2
ESS** 21 33.3
(*from Omura 1983; **from Sutton 1989,1992 and 1996)
Phase I study of high-dose IFO + DOX in
advanced sarcomas. Swiss Group Clinical Research
DOX 60-90 mg/m2 (divided in 2-3 days) + IFO 10-12 g/m2
(continous infusion over 5 days) + G-CSF
Enrolled patients : 33 (11 with gynecologic sarcoma) Evaluable patients: 31
From Leyvraz, 1998
CR 13%
PR 42%
3-year survival 25%
DOX 90 mg/m2 + IFO 10 g/m2 + G-CSF is manageable and should be tested in phase II trials
New drugs tested in advanced or recurrent uterine LMS
Drugs dose and schedule pts RR
Doxil 50 mg/m2 every 4 weeks 32* 5 (16%) Sutton 2005
Gemcitabine 1000 mg/m2 d 1,8, 15 42** 9 (20.5%)
every 4 weeks Look 2004
Gemcitabine 900 mg/m2 d 1,8
+ docetaxel 100 mg/m2 d 8 every 3 weeks 42* 15 (36%)
Hensley 2008
Gemcitabine 900 mg/m2 d 1,8
+ docetaxel 100 mg/m2 d 8 every 3 weeks 48** 13 (27%)
Hensley 2008
*chemonaive pts; **prechemotreated pts
Phase II study of adjuvant gemcitabine + docetaxel for completely resected stage I-IV high grade uterine LMS
Study population: 25 pts with completely resected stage I-IV LMS
Adjuvant CT: Gemcitabine 900 mg/m2 d 1, 8 + Docetaxel 75 mg/m2 d 8 (+ GCSF or pegfilgrastim) every 3 weeks x 4 cycles 23 evaluable pts
G3 toxicities: neutropenia, 8.7%; febrile neutropenia, 8.7%; anemia 8.7%; thrombocytopenia, 4.3%; diarrhea, 4.3%;
hyperglycemia, 8.7%; pulmonary 8.7%
With median follow-up of 49 months
Among all pts: 2-year PFS: 45%, median OS not yet reached.
Among the 18 pts in stage I-II: 2-y PFS: 59%, median OS not yet reached Gemcitabine/docetaxel yielded 2-y PFS superior to historical rates
Hensley 2009
Combination regimens with CDDP+DOX+ IFO in advanced CS
Seltzer 1980 6 5 (83) 3 (50)
Moore 1986 15 9 (60) 6 (40)
Grosh 1986 9 3 (33) 0
Wheelock 1986 3 1 (33) 1 (33)
Jansen 1987 6 5 (83) 2 (33)
Melviya 1988 11 8 (72) 6 (54)
Andersen 1989 6 6 (100) 4 (76)
Peters 1989 8 5 (62) 5 (62)
Plaxe 1990 5 2 (40) 1 (20)
Baker 1991 11 4 (36) 3 (27)
CTF 1997 17 11 (65) 6 (35)
Van Rijswijk 2003 32* 18 (56) 11 (34)
*Gynecological CS 129 77 (59) 48 (37)
authors pts RR (%) CR (%)
GOG randomized trial
Optimally debulked stage I,II III, or IV CS
Whole abdominal RT
IFO + CDDP
1.5 g/m2 d 1-4 20 mg/m2 d 1-4 x 3 cycles
RANDOM
versus
Randomised GOG trial in pts with stage I-IV MMT after optimal surgical debulking
WAI IFO + CDDP
1.5 g/m2 d 1-4 20 mg/m2 d 1-4 x 3 cycles
versus
206 pts with RD< 1 cm and no extra-abdominal disease
pts 5-y recurrence rate HR for CT (95% CI)
CT 101 52% 0.789 (0.530-1.176)
WAI 105 58%
Wolfson, 2007
Randomised GOG trial in pts with stage I-IV MMT after optimal surgical debulking
WAI IFO + CDDP
1.5 g/m2 d 1-4 20 mg/m2 d 1-4 x 3 cycles
versus
206 pts with RD< 1 cm and no extra-abdominal disease pts 5-y death rate HR for CT (95% CI)
CT 101 55% 0.712 (0.484-1.048)
WAI 105 65%
Wolfson, 2007
Phase III study of IFO + TAX in advanced uterine CS: a GOG study
Study population: 179 pts with stage III-IV, persistent or recurrent uterine CS
CT RR PFS OS sensory
months neuropathy
IFO 2 g/m2 d 1-3 29% 2 8.4 9%
IFO 1.6 g/m2 d 1-3 45% 5.8 13.5 30%
+ TAX 135 mg/m2 d 1
P value 0.017 0.03 0.03 <0.0001
Homesley
,
2007Phase III study of IFO + TAX in advanced uterine CS: a GOG study
IFO + TAX
HR for progression 0.71 95% CI, 0.51-0.97, p= 0.03 HR for death 0.69 95% CI, 0.49-0.97, p= 0.03
Homesley
,
2007pts RR
TAX (175 mg/m2) + CBDCA AUC 6 5 80%
Toyoshima 2004
TAX /Docetaxel + CBDCA/CDDP 38 63%
Leiser 2007
Phase II trials in advanced/recurrent CS
TAX (175 mg/m2) + CBDCA AUC 6 55 55%
Powell 2009
The GOG is currently conducting a randomised phase III trial (GOG 209), comparing DOX + TAX + CDDP vs TAX + CBDCA in endometrial cancer.
Similarly, a randomized trial evaluating the efficacy and toxicity of CBDCA+ TAX vs CDDP + IFO in advanced or recurrent uterine CS is warranted
Chemotherapy in advanced/recurrent CS
Anecdotal response of LG-ESS to Gn-RH analogues (Scribner 1998; Mesia 2000; Burke 2004) and to letrozole (Maluf 2001, Pink 2006, Brechot 2007)
High recurrence rate of LG-ESS pts placed on ERT following TAH + BSO (Schwartz 2002, Lo 2005, Pink 2006)
LG-ESS: Hormonal sensitive tumors
High incidence of recurrence of LG-ESS when the ovaries are left in place in premenopausal women
ER and PR expression in LG-ESS
Advanced LG-ESS will regress with progestin: several small series in literature
LG-ESS: Hormonal sensitive tumors
Little evidence in the literature supporting the use of adjuvant CT in any gynaecological sarcomas except CS
Uterine sarcomas have a high tendency to distant recurrences, and recent data on adjuvant CT in STSs are promising
Uterine sarcoma pts should be treated within randomised trials (difficult to be conducted because of their rarity)
As for the drugs to be used, IFO + DOX obtained similar RR in advanced gynaecological sarcomas and in STSs of other sites
Gemcitabine + taxotere: good results in LMS
CDDP-based CT is effective in CS
Conclusions
Classificazione FIGO 2008: LMS
Stadio I: tumore limitato all’utero Ia: < 5 cm
Ib: > 5 cm
Stadio II: il tumore si estende oltre la pelvi IIa: c’è interessamento degli annessi
IIb: estensione ai tessuti pelvici extrauterini Stadio III: il tumore invade i tessuti addominali
IIIa: interessa una sola sede IIIb: coinvolgimento di più sedi
IIIc: linfonodi pelvici e/o paraortici positivi
Stadio IVa: invasione della mucosa vescicale o rettale IV b: metastasi a distanza
Leiomiosarcoma (LMS): indicazioni terapeutiche
A) L’isterectomia totale (ITA) è il trattamento standard nel I stadio . In età perimenopausale/menopausale è raccomandata anche l’annessiectomia bilaterale (SOB)
C) Interventi conservativi (miomectomia) solo in centri con expertise, in donne giovani nullipare desiderose di prole, se il tumore ha dimensioni < 5 cm (stadio IA).
B) ITA-SOB è il trattamento standard nel II stadio
B) Nel I-II stadio I-II : può essere proposta CT adiuvante con regimi contenenti DOX + IFO o gemcitabina + taxotere.
Classificazione FIGO 2008: sarcoma stroma endometriale e adenosarcoma
Stadio I: tumore limitato all’utero
Ia: limitato all’endometrio/endocervice (no invasione miometriale)
Ib: invade meno di metà del miometrio Ic: invade più di metà miometrio
Stadio II: il tumore si estende oltre la pelvi IIa: interessamento degli annessi
IIb: estensione ai tessuti pelvici extrauterini Stadio III: il tumore invade i tessuti addominali
IIIa: interessa una sola sede IIIb: coinvolgimento di più sedi
IIIc: linfonodi pelvici e/o paraortici positivi
Stadio IVa: invasione della mucosa vescicale o rettale IV b: metastasi a distanza
Sarcoma dello stroma endometriale (SSE): Indicazioni terapeutiche
A) ITA-SOB è il trattamento standard nel I stadio .
C) Interventi conservativi (miomectomia) solo in centri con expertise, in donne giovani nullipare desiderose di prole adeguatamente informate.
C) Ormonoterapia adiuvante, selezionata in base all’assetto recettoriale, può essere proposta nel I-II stadio
C) RT precauzionale può essere proposta su base individualizzata nel I-II stadio
Sarcoma dello stroma endometriale (SSE): Indicazioni terapeutiche
B) Stadio III con malattia resecabile: è raccomandata chirurgia completa (ITA-SOB, chirurgia citoriduttiva, ed eventualemente linfadenectomia pelvica e lombo-aortica) seguita da ormonoterapia
C) Stadio III con malattia completamente recata: CT con DOX + IFO è proponibile in casi accuratamente selezionati (elevato indice mitotico, RE-, RP-).
RT in casi selezionati in relazione alla presenza di fattori di rischio.
B) Stadio avanzato non resecabile: Ormonoterapia è il trattamento primario.
CT con DOX + IFO riservata a tumori non ormonoresponsivi.
RT va proposta sulla base della sintomatologia.
Sarcoma endometriale indifferenziato: indicazioni terapeutiche
A) ITA-SOB è il trattamento standard nello stadio I- II.
B) CT adiuvante con DOX + IFO e’ generalmente offerta in stadio I-II.
C) RT adiuvante può essere proposta su base individualizzata in stadio I- II.
B) CT è il trattamento standard nella malattia localmente avanzata. RT va tenuta in considerazione sulla base della sintomatologia.
Classificazione FIGO 2008: carcinosarcoma
Stadio Ia: limitato all’endometrio o infiltrazione miometriale < 50%
Ib: infiltrazione miometriale > 50%
Stadio II: invasione dello stroma cervicale^
Stadio IIIa: invasione della sierosa del corpo uterino e/o gli annessi*
IIIb: invasione vaginale o parametriale IIIc1: linfonodi pelvici positivi
IIIc2: linfonodi paraortici positivi con o senza linfonodi pelvici positivi
Stadio IVa: invasione della mucosa vescicale e/o rettale
IV b: metastasi a distanza (incluse le metastasi intraddominali e/o ai linfonodi inguinali)
^l’interessamento ghiandolare endocervicale da solo deve essere considerato come stadio I e non come stadio II
*la citologia peritoneale positiva deve essere riportata separatamente ma non modifica lo stadio
Carcinosarcoma (CS): indicazioni terapeutiche
A) ITA-SOB con stadiazione chirurgica è il trattamento standard nel I-II stadio.
B) Nel I-II stadio I-II : può essere proposta CT adiuvante con regimi contenenti CDDP + IFO + DOX o CBDCA + TAX.
C) RT precauzionale può essere proposta su base individualizzata nel I-II stadio